Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide on BAT Activity in Healthy Men
NCT03002675Phase 4Unknown
- Sponsor
- Ingrid Jazet
- Start
- Aug 2016
- Primary completion
- Jun 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of exenatide in obesity, sponsored by Ingrid Jazet. Primary endpoints: Brown Adipose Tissue activity at 12 weeks and Resting Energy Expenditure at 12 weeks. Status: unknown.
02
Drugs
exenatide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT03002675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03002675.